S. Abidi, I. Mian, I. Garcia-ortega, T. Lecomte, T. Raedler et al., CPA Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth, Can. J. Psychiatry Rev. Can. Psychiatr, 2017.

D. Addington, J. Addington, and E. Maticka-tyndale, Assessing depression in schizophrenia: the Calgary Depression Scale, Br. J. Psychiatry, pp.39-44, 1993.

K. G. Alberti, P. Zimmet, and J. Shaw, Metabolic syndrome-a new worldwide definition. A Consensus Statement from the International Diabetes Federation, Diabet. Med, vol.23, pp.469-480, 2006.

R. Bender and S. Lange, Adjusting for multiple testing-when and how?, J. Clin. Epidemiol, vol.54, pp.343-349, 2001.

M. Berk, L. J. Williams, F. N. Jacka, A. O'neil, J. A. Pasco et al., So depression is an inflammatory disease, but where does the inflammation come from, BMC Med, vol.11, 0200.

E. Bulzacka, L. Boyer, F. Schürhoff, O. Godin, F. Berna et al., FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group, 2016. Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset

A. B. Cuéllar-barboza, J. A. Sánchez-ruiz, and P. M. Corral, , 2017.

, Polyunsaturated Fatty Acids as Augmentation Therapy in Treatment-Resistant Schizophrenia, Prim. Care Companion CNS Disord, vol.19

N. Sarwar, P. Gao, S. R. Seshasai, R. Gobin, S. Kaptoge et al., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies, Lancet Lond. Engl, vol.375, issue.10, pp.60484-60493, 2010.

B. S. Fernandes, J. Steiner, H. Bernstein, S. Dodd, J. A. Pasco et al., C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications, Mol. Psychiatry, vol.21, pp.554-564, 2016.

E. Fernandez-egea, P. E. Vértes, S. M. Flint, L. Turner, S. Mustafa et al., Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia, PloS One, vol.11, 2016.

G. Fond, M. Albis, S. Jamain, R. Tamouza, C. Arango et al., The promise of biological markers for treatment response in first-episode psychosis: a systematic review, Schizophr. Bull, vol.41, pp.559-573, 2015.

G. Fond, N. Hamdani, F. Kapczinski, W. Boukouaci, N. Drancourt et al., Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review, Acta Psychiatr. Scand, vol.129, pp.163-179, 2014.

A. Hasan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthøj et al., World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation, WFSBP Task Force on Treatment Guidelines for Schizophrenia, 2015.

, Soc. Biol. Psychiatry, vol.16, pp.142-170

A. Hasan, T. Wobrock, W. Gaebel, B. Janssen, J. Zielasek et al., National and international schizophrenia guidelines. Update 2013 regarding recommendations about antipsychotic pharmacotherapy, Nervenarzt, vol.84, pp.1366-1368, 2013.

H. T. Horsdal, T. Wimberley, M. E. Benros, and C. Gasse, C-reactive protein levels and treatment resistance in schizophrenia-A Danish population-based cohort study, Hum. Psychopharmacol, vol.32, 2017.

O. D. Howes, R. Mccutcheon, O. Agid, A. De-bartolomeis, N. J. Van-beveren et al., Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology, Am. J. Psychiatry, vol.174, pp.216-229, 2017.

O. D. Howes, R. Mccutcheon, O. Agid, A. De-bartolomeis, N. J. Van-beveren et al., Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology, Am. J. Psychiatry, vol.174, pp.216-229, 2017.

F. Iasevoli, S. Giordano, R. Balletta, G. Latte, M. V. Formato et al., Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.65, pp.34-48, 2016.

M. Inoshita, S. Numata, A. Tajima, M. Kinoshita, H. Umehara et al., A significant causal association between C-reactive protein levels and schizophrenia, Sci. Rep, vol.6, 2016.

J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine, Arch. Gen. Psychiatry, vol.45, pp.789-796, 1988.

S. Kartalci, A. B. Karabulut, L. G. Erbay, and C. Acar, Effects of Electroconvulsive Therapy on Some Inflammatory Factors in Patients With Treatment-Resistant Schizophrenia, J. ECT, vol.32, pp.174-179, 2016.

S. R. Kay, A. Fiszbein, and L. A. Opler, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull, vol.13, pp.261-276, 1987.

D. Keating, S. Mcwilliams, I. Schneider, C. Hynes, G. Cousins et al., Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode, BMJ Open, vol.7, 2017.

G. M. Khandaker, L. Cousins, J. Deakin, B. R. Lennox, R. Yolken et al., Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment, Lancet Psychiatry, vol.2, issue.14, pp.122-131, 2015.

S. Leucht, A. Cipriani, L. Spineli, D. Mavridis, D. Orey et al., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet Lond. Engl, vol.382, pp.60733-60736, 2013.

S. Leucht, J. M. Kane, W. Kissling, J. Hamann, E. Etschel et al., What does the PANSS mean?, Schizophr. Res, vol.79, pp.231-238, 2005.

S. Leucht, I. Winter-van-rossum, S. Heres, C. Arango, W. W. Fleischhacker et al., The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics, Schizophr. Bull, vol.41, pp.549-558, 2015.

J. Lindenmayer, H. Liu-seifert, P. M. Kulkarni, B. J. Kinon, V. Stauffer et al., Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response, J. Clin. Psychiatry, vol.70, pp.990-996, 2009.

T. L. Lo, M. Warden, Y. He, T. Si, S. Kalyanasundaram et al., Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region, Asia-Pac. Psychiatry Off. J. Pac. Rim Coll. Psychiatr, vol.8, pp.154-171, 2016.

A. L. Lopresti, G. L. Maker, S. D. Hood, and P. D. Drummond, A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.48, pp.102-111, 2014.

H. Y. Meltzer, Treatment-resistant schizophrenia--the role of clozapine, Curr. Med. Res. Opin, vol.14, pp.1-20, 1997.

D. Misdrahi, H. Verdoux, P. Llorca, and F. Baylé, , 2004.

V. Mondelli, S. Ciufolini, M. Belvederi-murri, S. Bonaccorso, M. Di-forti et al., Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis, Schizophr. Bull, vol.41, pp.1162-1170, 2015.

S. Nishimon, T. Ohnuma, Y. Takebayashi, N. Katsuta, M. Takeda et al., High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.76, pp.145-154, 2017.

M. Nitta, T. Kishimoto, N. Müller, M. Weiser, M. Davidson et al., Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials, Schizophr. Bull, vol.39, pp.1230-1241, 2013.

B. B. Ortiz, F. D. Eden, A. S. De-souza, C. A. Teciano, D. M. De-lima et al., New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage, Compr. Psychiatry, vol.73, pp.93-96, 2017.

J. Peuskens, The evolving definition of treatment resistance, J. Clin. Psychiatry, vol.60, pp.4-8, 1999.

T. Pollmächer, D. Hinze-selch, and J. Mullington, Effects of clozapine on plasma cytokine and soluble cytokine receptor levels, J. Clin. Psychopharmacol, vol.16, pp.403-409, 1996.

G. Remington, D. Addington, W. Honer, Z. Ismail, T. Raedler et al., Guidelines for the Pharmacotherapy of Schizophrenia in Adults, Can. J. Psychiatry Rev. Can. Psychiatr, 2017.

S. L. Rossell, P. S. Francis, C. Galletly, A. Harris, D. Siskind et al., N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms, BMC Psychiatry, vol.16, 2016.

L. Samalin, M. Abbar, P. Courtet, S. Guillaume, S. Lancrenon et al., , 2013.

, L'Encephale, vol.39, pp.189-203

F. Schürhoff, G. Fond, F. Berna, E. Bulzacka, J. Vilain et al., FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) collaborators, 2015. A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap, Eur. Psychiatry J. Assoc. Eur. Psychiatr

D. Siskind, V. Siskind, and S. Kisely, Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis, Can. J. Psychiatry Rev. Can. Psychiatr, 2017.

I. E. Sommer, R. Van-westrhenen, M. J. Begemann, L. D. De-witte, S. Leucht et al., Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update, Schizophr. Bull. sbt139, 2013.

S. M. Stahl, D. A. Morrissette, L. Citrome, S. R. Saklad, M. A. Cummings et al., Meta-guidelines" for the management of patients with schizophrenia, CNS Spectr, vol.18, pp.150-162, 2013.

M. Startup, M. C. Jackson, and S. Bendix, The concurrent validity of the Global Assessment of Functioning (GAF), Br. J. Clin. Psychol, vol.41, pp.417-422, 2002.

M. T. Strassnig and P. D. Harvey, Treatment resistance and other complicating factors in the management of schizophrenia, CNS Spectr, vol.19, issue.1, pp.16-23, 2014.

R. S. Sultan, M. Olfson, C. U. Correll, and E. J. Duncan, Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring, J. Clin. Psychiatry, 2017.

T. Suzuki, H. Uchida, K. Watanabe, and H. Kashima, Factors associated with response to clozapine in schizophrenia: a review, Psychopharmacol. Bull, vol.44, pp.32-60, 2011.

R. C. Young, J. T. Biggs, V. E. Ziegler, and D. A. Meyer, A rating scale for mania: reliability, validity and sensitivity, Br. J. Psychiatry, vol.133, pp.429-435, 1978.